EBSA07 Conference - Prague 2004

Biosafety risk assessment, containment and safe disposal

PRAGUE, CZECH REPUBLIC
13 - 14 MAY 2004

Programme

THURSDAY, 13 MAY 2004

 

Registration 08.00
Trends in Containment Lab Design 08.15 - 09.30
Breakfast workshop sponsored by CUH2A  
Welcome by EBSA President Kathrin Bernard 09.30-09.40
Session 1: Risk Assessment, (re)emerging diseases 09.40-10.35
Chair: Prof. Ing. Jan Kas, DrSc., Dept. of Biochemistry and Microbiology,
Institute of Chemical Technology, Prague

Emerging Viral Infections, what is the risk and are we prepared?
Dr. Maria Zambon, Enteric, Respiratory & Neurological Virus Reference
Laboratory, Specialist & Reference Microbiology Division, London

 
Break 10.35-11.05
Session 2: Risk Assessment - Concurrent Breakout Sessions (discussion groups)  
Session 2 A: Animal risk assessment 11.05-12.30
Moderator: Dr. Kathrin Bernard, Institute for Virology and Immunoprophylaxis, Berne, Switzerland

Work in biocontainment facilities involving animals must include continuous and rational risk assessment. The basic elements include understanding the biology of the agents and the potential hazards associated with non-infected or infected animals. Physical and biological hazards should be assessed and appropriate safety measures should be taken. This breakout session will focus on how hazardous agents can be prevented from spreading from experimentally or naturally infected animals to other animals or to people.

 
Session 2 B: GMO Risk Assessment 11.05-12.30
Moderator: Dr. Gary Burns, AstraZeneca , UK

This will be an interactive session addressing risk assessment of work involving genetically modified organisms within the context of European Council Directive 98/81/EC. Among the issues to be addressed will be:
·dealing with uncertainty
·usefulness (or otherwise) of quantitative/semi-quantitative approaches
·pros and cons of risk classification based on selection of control measures

 
Session 2 C: Large Scale Risk Assessment 11.05-12.30
Moderator: Dr. Otto Doblhoff, Igeneon, Austria

The discussion will focus on, but will not be limited to:
·Product safety versus biosafety (where are the critical differences?)
·New production processes in need of elevated biosafety measures(gene therapy vectors, high potency biomolecules)
·Equipment update (e.g. disposables, isolators)
·Monitoring techniques

 
Session 2D: Transport Risk Assessment 11.05-12.30
Moderator: Nicholas Mohr, Peter East Associates, UK
Speakers: Janet Cox, Roche, UK and Sue Lee, World Courier, UK

This session will address the key issues relating to the transport of diagnostic, clinical and infectious specimens as they impact the shippers, intermediaries and airlines. The regulations for classification, packaging, documentation, acceptance by carriers as well as temperature control have developed in response to risk assessment. Yet, do all the participants in the transport chain have a similar understanding of the risks. What are the risks involved with international transport? Are major changes in the regulations effective from January 2005 based on sound principles of risk assessment? And finally, does training play any relevant role in mitigating the risk inherent in transport? There will some short presentations followed by a discussion of the issues raised.

 
Managing Biosafety - Insights From Other Major Hazard Industries 12.30 - 14.00
Luncheon workshop sponsored by DNV  
Session 3: Containment Principles - Laboratory Versus Hospital Settings 14.00 - 15.00
Laboratory Containment Measures for Mycobacterium tuberculosis
Alan Rayner, Chief Biomedical scientist, Scottish Mycobacteria reference Laboratory,
Royal infirmary of Edinburgh, UK
14.00 - 14.30
Worker protection against M. tuberculosis in patient care, diagnosis and pathology
Dr. Juergen Mertsching, Biosafety Officer, Hannover Medical School, Germany
14.30-15.00
Break 15.00 - 15.30
Session 4: Containment Principles - Monitoring for Exposure
Convener: Esmeralda Prat, Bayer CropScience, Belgium
Chair: Stefan Wagener, CSCHAH, Winnipeg, Canada
15.30 - 17.00
Introduction: Why monitor?
Stefan Wagener, CSCHAH, Winnipeg, Canada
15.30-15.35

Monitoring viral contaminations in laboratories during biosafety inspections
Guido Vogel, Claudia Bagutti, Urs Vögeli, André Herrmann, Biological and Chemical Safety
Administration, Basel, Switzerland

15.35-16.00
Monitoring bacteria and yeast in the laboratory
Jan-Piet Tijssen, VROM-Inspectorate, Haarlem, The Netherlands
16.00-16.25
Quantification of aerosol generation in laboratory procedures and the potential worker exposure
Allan Bennett, Health Protection Agency, Salisbury, UK
16.25- 16.50

Discussion: meaning of results

Lead by Stefan Wagener

16.50-17.00
ANNUAL GENERAL MEETING for EBSA Members only 17.00 - 18.00

CONFERENCE RECEPTION AND DINNER

Pick-up at hotel - Timetable: see EBSA welcome desk

20.00


FRIDAY, 14 May 2004

 

 

Session 5: Waste Management
Chair: Mr. Robert Osborne, University of Glasgow, UK
09.00-10.00
Management of Infectious Waste
Ms Wendy Rayner, Enviros Consulting Ltd, Edinburgh Office: 61 The Shore,
Leith. Edinburgh, UK
09.00-09.30
Waste water management in biopharmaceutical production
Dr. Roman Necina, Head of Biotech Production, Boehringer Ingelheim Austria, Vienna
09.30-10.00
Break and Poster session 10.00-11:00
Session 5: Waste Management (continued) 11.00-11.30
New and Emerging Technologies for Clinical Waste Disposal
Dr. M.G. Holliday, Microbiology Department, Newcastle-upon Tyne Hospitals NHS Trust
 
Session 6: Chris Collins Lecture 11.30-12.15
Investigation of 1918 Spanish flu using permafrost burials and pathology lung blocks
Dr. Rod Daniels, National Institute for Medical Research, London, UK
 
Closure by the EBSA president 2004-2005 Prof. Helmut Bachmayer 12.15
Sandwich Lunch 12.30-13.00